HIV-1 protease-IN-6_product_DataBase

Bioactivity	HIV-1 protease-IN-6 (compound 17d) is a potent HIV-1 protease inhibitor, with an IC50 of 21 pM and a Ki of 4.7 pM, respectively. HIV-1 protease-IN-6 exhibits potent antiviral activity to DRV (darunavir)-resistant variant, even more than wild type virus[1].
Target	IC50: 0.021 nM (HIV-1 protease)EC50: 0.74 μM (HIV-1 NL4−3), 0.61 μM (HIV DRVRs)
Invitro	HIV-1 protease-IN-6 (compound 17d) (10 μM; 48 h) exhibits full inhibition against the late stage of HIV-1 replication cycle while the inhibition rate is 2.6% on early stage at the cellular level[1].HIV-1 protease-IN-6 (10 μM; 24 h) displays antiviral activity against HIV-1NL4-3 with an EC50 value of 0.74 μM, and exhibits anti-DRV-resistant tendency with an EC50 value of 0.61 μM towards DRV-resistant variant[1].
Name	HIV-1 protease-IN-6
Formula	C27H31FN2O6S
Molar Mass	530.61
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Hu S, et al. A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants. Bioorg Med Chem. 2022 Jun 15. 64:116760.

PeptideDB